复方羚角降压片联合福辛普利治疗原发性高血压的临床研究

Clinical study on Compound Lingjiao Jiangya Tablets combined with fosinopril in treatment of primary hypertension

目的探讨复方羚角降压片联合福辛普利钠片治疗原发性高血压的临床疗效。方法选取2019年1月—2019年12月在河南省中医药研究院附属医院就诊的138例原发性高血压患者,随机分为对照组和治疗组,每组各69例。对照组口服福辛普利钠片,10 mg/次,1次/d;治疗组在对照组的基础上口服复方羚角降压片,3片/次,3次/d。两组患者均治疗12周。观察两组患者临床疗效,比较治疗前后两组患者血压变异性,血清血管内皮生长因子(VEGF)、内皮素1(ET-1)和一氧化氮(NO)、超敏C反应蛋白(hs-CRP)和白细胞介素6(IL-6)水平。结果治疗后,治疗组总有效率为94.20%,显著高于对照组的82.61%(P<0.05)。治疗后,两组24 h收缩压(SBP)、24 h舒张压(DBP)、收缩压变异性(SBPV)和舒张压变异性(DBPV)均显著降低(P<0.05),与对照组相比,治疗组降低更显著(P<0.05)。治疗后,两组VEGF、ET-1、hs-CRP和IL-6水平均显著下降,而NO水平显著升高(P<0.05),且治疗组这些指标水平显著优于对照组(P<0.05)。结论复方羚角降压片联合福辛普利钠片治疗原发性高血压疗效显著,能有效改善患者血管内皮细胞功能和炎症状态,具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Compound Lingjiao Jiangya Tablets combined with Fosinopril Sodium Tablets in treatment of primary hypertension.Methods Patients(138 cases)with primary hypertension in the Affiliated Hospital of Henan Academy of Chinese Medicine from January 2019 to December 2019 were randomly divided into control and treatment groups,and each had 69 cases.Patients in the control group were po administered with Fosinopril Sodium Tablets,10 mg/time,once daily.Patients in the treatment group were po administered with Lingjiao Jiangya Tablets on the basis of the control group,3 tablets/time,three times daily.Patients in two groups were treated for 12 weeks.After treatment,the clinical efficacy was evaluated,and the blood pressure variability,and the serum levels of VEGF,ET-1,NO,hs-CRP and IL-6 in two groups before and after treatment were compared.Results After treatment,the clinical effective rate in the treatment group was 94.20%,which was significantly higher than 82.61%in the control group(P<0.05).After treatment,the 24 h SBP,24 h DBP,SBPV,and DBPV levels in two groups were significantly decreased(P<0.05),and compared with the control group,the treatment group decreased more significantly(P<0.05).After treatment,the serum levels of VEGF,ET-1,hs-CRP and IL-6 in the two groups were significantly decreased,while the levels of NO were significantly increased(P<0.05),and the levels of these indexes in the treatment group were significantly better than those in the control group(P<0.05).Conclusion Compound Lingjiao Jiangya Tablets combined with Fosinopril Sodium Tablets has a significant clinical efficacy in treatment of primary hypertension,can significantly improve the vascular endothelial cell function and decrease inflammatory status,which has a certain clinical application value.